Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Acorda Therapeutics, Inc. (ACOR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Acorda Therapeutics Reports Second Quarter 2023 Financial Results • INBRIJA® Q2 2023 U.S. net revenue of $8.3 million, a 12% increase from Q2 2022; ex-U.S. net revenue of $0.8 million • New INBRIJA prescription request forms increased 42% in 1H 2023 over 2022 • AMPYRA® Extended Release Tablets, 10 mg Q2 2023 net revenue of $16.9 million, a 7% decrease from Q2 2022; FAMPYRA royalty revenue of $2.9 million • 2023 INBRIJA U.S. net revenue, adjusted operating expenses, and year-end cash guidance revised • Company does not expect to be cash flow neutral in 2023 • Nasdaq compliance regained after 1-for-20 reverse split"
06/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FIRST: The name of the Corporation is Acorda Therapeutics, Inc. SECOND: The registered office of the Corporation is to be located at 1209 Orange Street, Wilmington, , Delaware 19801. The name of its registered agent at that address is The Corporation Trust Company. THIRD: The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the General Corporation Law of Delaware. FOURTH: The Corporation shall have the authority to issue a total of 23,083,333 shares, divided into classes of 3,083,333 shares of Common Stock, $0.001 par value per share , and 20,000,000 shares of Preferred Stock, $0.001 par value per share . Pursuant to the DGCL, at 4:01 p.m. Eastern Time on the date of filing of this Amended and Restated Certificate of Incor...",
"Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split"
06/01/2023 8-K Other Events  Interactive Data
05/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Acorda Therapeutics Reports First Quarter 2023 Financial Results • INBRIJA® Q1 2023 U.S. net revenue of $5.6 million, a 52% increase from Q1 2022; ex-U.S. net revenue of $0.5 million • AMPYRA® Extended Release Tablets, 10 mg Q1 2023 net revenue of $12.6 million, a 15% decrease from Q1 2022; FAMPYRA royalty revenue of $2.9 million • 2023 financial guidance reaffirmed • Agreement with Chance Pharmaceuticals to commercialize INBRIJA in China • Tom Burns, Chief Financial Officer of XOMA, to be candidate for Board of Directors at 2023 Annual Meeting of Stockholders; Jeff Randall to rotate off the Board"
05/10/2023 SC 13D/A DAVIDSON KEMPNER CAPITAL MANAGEMENT LP reports a 4.5% stake in Acorda Therapeutics, Inc.
05/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash"
05/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China"
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/04/2023 4 COHEN RON (President and CEO) has filed a Form 4 on Acorda Therapeutics, Inc.
Txns: Granted 168,800 options to buy @ $0.586, valued at $98.9k
04/04/2023 4 Clem Kerry M (Chief Commercial Officer) has filed a Form 4 on Acorda Therapeutics, Inc.
Txns: Granted 77,300 options to buy @ $0.586, valued at $45.3k
04/04/2023 4 Belloff Neil S. (General Counsel and Corp Secy) has filed a Form 4 on Acorda Therapeutics, Inc.
Txns: Granted 77,300 options to buy @ $0.586, valued at $45.3k
03/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/10/2023 SC 13D/A DAVIDSON KEMPNER CAPITAL MANAGEMENT LP reports a 7.4% stake in Acorda Therapeutics, Inc.
02/14/2023 SC 13G/A CANYON CAPITAL ADVISORS LLC reports a 0% stake in Acorda Therapeutics Inc
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/23/2023 SC 13D/A DAVIDSON KEMPNER CAPITAL MANAGEMENT LP reports a 8.6% stake in Acorda Therapeutics, Inc.
01/05/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA ®"
01/04/2023 4 Varian John (Director) has filed a Form 4 on ACORDA THERAPEUTICS INC
Txns: Granted 4,712 options to buy @ $0.7667, valued at $3.6k
12/23/2022 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/22/2022 8-K Quarterly results
12/21/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders"
11/07/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/04/2022 8-K Quarterly results
11/01/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/01/2022 8-K Quarterly results
10/31/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/31/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy